Company intelligence / Profile preview

IC-MedTech

El Cajon, California, United Statesic-medtech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

IC-MedTech has developed intellectual property around small molecule therapies that selectively target cellular redox processes in diseased cells. Their approach leverages both repurposed and novel compounds for oncology, infectious disease, inflammatory and genetic disease indications. The science remains emerging with no currently approved drugs from this platform; peer-reviewed publications support their rationale but there are no reported pivotal clinical results yet.

Therapeutic areas: OncologyImmunologyRare DiseasesInfectious Diseases
Modalities: Small moleculesFixed combination drugsRepurposed drugsNew chemical entities
Industry: Biotech

Drug pipeline

1 asset

ICM20

Partnerships

Collaborations with hospitals, academia, and commercial entities globally for research funding related to their drug discovery approach.

Beyond the preview

Go deeper on IC-MedTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IC-MedTech.